See more : JDC Corporation (1887.T) Income Statement Analysis – Financial Results
Complete financial analysis of Invivyd, Inc. (IVVD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Invivyd, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ruentex Materials Co.,Ltd. (8463.TW) Income Statement Analysis – Financial Results
- Bangkok Commercial Asset Management Public Company Limited (BAM.BK) Income Statement Analysis – Financial Results
- Charter Hall Group (CTOUF) Income Statement Analysis – Financial Results
- fonfun corporation (2323.T) Income Statement Analysis – Financial Results
- Magnora ASA (SVMRF) Income Statement Analysis – Financial Results
Invivyd, Inc. (IVVD)
About Invivyd, Inc.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.03M | 462.00K | 1.00K | 0.00 |
| Gross Profit | -2.03M | -462.00K | -1.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 158.66M | 179.21M | 182.89M | 62.12M |
| General & Administrative | 0.00 | 47.04M | 36.52M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.10M | 47.04M | 36.52M | 3.21M |
| Other Expenses | 0.00 | 6.71M | 118.00K | 0.00 |
| Operating Expenses | 205.76M | 226.26M | 219.41M | 65.33M |
| Cost & Expenses | 207.78M | 226.26M | 219.41M | 65.33M |
| Interest Income | 0.00 | 6.71M | 118.00K | 8.00K |
| Interest Expense | 0.00 | 43.08M | 0.00 | 0.00 |
| Depreciation & Amortization | 2.03M | 462.00K | 1.00K | 43.20M |
| EBITDA | -196.62M | -248.03M | -226.79M | -65.33M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -207.78M | -248.03M | -226.91M | -65.33M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.14M | 6.71M | -7.38M | 8.00K |
| Income Before Tax | -198.64M | -241.32M | -226.79M | -65.32M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.71M | 7.50M | -43.20K |
| Net Income | -198.64M | -234.60M | -234.29M | -65.32M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.81 | -2.17 | -2.11 | -0.59 |
| EPS Diluted | -1.81 | -2.17 | -2.11 | -0.59 |
| Weighted Avg Shares Out | 109.53M | 108.27M | 110.78M | 111.25M |
| Weighted Avg Shares Out (Dil) | 109.53M | 108.27M | 110.78M | 111.25M |
What's Going On With Adagio Therapeutics Stock Today?
Why Adagio Therapeutics Stock Is Falling Again Today
ADGI Stock Alert: The Omicron Variant Just Sent Adagio Therapeutics Plunging
Why Are Adagio Shares Plunging Today?
Will Adagio's COVID Antibody Therapy Be Too Late to the Party?
Adagio Therapeutics stock outlook as shares spike 35% on social media chatter
Adagio Therapeutics extends 3-day gain to 319% on hopes that its antiviral can treat the Omicron variant
ADGI Stock: The Social Media Chatter That Has Adagio Therapeutics Soaring Today
Morgan Stanley: Omicron will benefit this relatively new biotech firm
4 Top Biotech Stocks To Watch Now
Source: https://incomestatements.info
Category: Stock Reports